A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy With a 24-Week Open-Label Extension.

Trial Profile

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy With a 24-Week Open-Label Extension.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2014

At a glance

  • Drugs Belnacasan (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Vertex
  • Most Recent Events

    • 15 Jan 2014 Status changed from active, no longer recruiting to discontinued according to ClinicalTrials.gov.
    • 02 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 23 Jun 2012 New source identified and integrated (EudraCT2011-004156-19: European Clinical Trials Database).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top